Spruce Biosciences (SPRB) Expected to Announce Earnings on Monday

Spruce Biosciences (NASDAQ:SPRB) is expected to announce its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect Spruce Biosciences to post earnings of ($15.56) per share for the quarter. Investors can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 10, 2025 at 4:00 PM ET.

Spruce Biosciences Trading Up 2.7%

Shares of Spruce Biosciences stock opened at $110.10 on Monday. Spruce Biosciences has a 12-month low of $4.28 and a 12-month high of $240.00. The company has a market cap of $55.27 million, a P/E ratio of -1.28 and a beta of 2.47. The company’s fifty day simple moving average is $63.07 and its two-hundred day simple moving average is $26.71.

Analyst Ratings Changes

SPRB has been the subject of a number of research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Spruce Biosciences in a research note on Tuesday, October 14th. Citigroup raised Spruce Biosciences to an “outperform” rating in a research report on Tuesday, October 28th. JMP Securities set a $254.00 target price on Spruce Biosciences and gave the stock a “market outperform” rating in a research report on Tuesday, October 28th. Citizens Jmp upgraded Spruce Biosciences from a “market perform” rating to an “outperform” rating and set a $254.00 price target on the stock in a research report on Tuesday, October 28th. Finally, Leerink Partners set a $160.00 price objective on Spruce Biosciences and gave the stock a “market perform” rating in a report on Tuesday, October 21st. Three research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Spruce Biosciences currently has a consensus rating of “Hold” and a consensus price target of $176.38.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.